ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "classification criteria"

  • Abstract Number: 0711 • ACR Convergence 2024

    Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis

    Natania Field1, Monica Yang2, Niket Gupta1, Maxwell Shramuk1, Lutfiyya Muhammad1, Vivien Goh1, Monica Espinoza3, Yiwei Yuan3, Rezvan Parvizi3, Kathleen Aren4, Mary Carns4, Isaac Goldberg5, Lorinda Chung6, Dinesh Khanna7, Zsuzsanna McMahan8, Michael Whitfield3 and Monique Hinchcliff9, 1Northwestern Feinberg School of Medicine, Chicago, IL, 2UCSF, San Francisco, CA, 3Geisel School of Medicine at Dartmouth, Hanover, NH, 4Northwestern University Division of Rheumatology, Chicago, IL, 5Wayne State University School of Medicine, Detroit, MI, 6Stanford University, Woodside, CA, 7University of Michigan, Ann Arbor, MI, 8UTHealth Houston Division of Rheumatology, Houston, TX, 9Yale School of Medicine, Westport, CT

    Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
  • Abstract Number: 0820 • ACR Convergence 2024

    The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria

    Walter Maksymowych1, Desiree van der Heijde2, Liron Caplan3, Robert Landewé4, Lianne S Gensler5, Pedro M. Machado6, Alexandre Sepriano7, Floris van Gaalen8, Miranda van Lunteren9, Ben Vandermeer10, Joachim Sieper11, Atul Deodhar12 and Martin Rudwaleit13, and on behalf of CLASSIC Study investigators, 1University of Alberta, Edmonton, AB, Canada, 2Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 3Rocky Mountain Regional VAMC, Aurora, CO, 4Amsterdam University Medical Center, Meerssen, Netherlands, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 7Leiden University Medical Centre, Portela Loures, Portugal, 8LUMC, Leiden, Zuid-Holland, Netherlands, 9Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 10University of Alberta, Edmonton, Canada, 11Charité University Medicine Berlin, Berlin, Germany, 12Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 13University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany

    Background/Purpose: The 2009 ASAS classification criteria had sensitivity of 83% and specificity of 84% for a rheumatologist diagnosis of axSpA. However, their implementation revealed varying…
  • Abstract Number: 1118 • ACR Convergence 2024

    The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3 and Omer Pamuk4, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…
  • Abstract Number: 1122 • ACR Convergence 2024

    Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management

    Chloe Heiting1, Karen Gambina2 and Bella Mehta3, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medical College, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Adult Onset Still’s Disease (AOSD) is a rare systemic inflammatory disorder characterized by inflammatory polyarthritis, daily fever, and a transient salmon-pink maculopapular rash. Diagnosis…
  • Abstract Number: 1205 • ACR Convergence 2024

    OARSI Initiative to Develop Classification Criteria for Early-Stage Symptomatic Knee OA (EsSKOA): What Should Be Considered in the Differential Diagnosis of EsSKOA?

    Gillian Hawker1, Lauren King1, Jean Liew2, Quike Wang3, Armaghan Mahmoudian4, Nuria Jansen5, Ian Stanaitis6, Jos Runhaar5, Tom Appleton7, Aleksandra Turkiewicz8, Martin Englund9, Stefan Lohmander9, Ida Kristin Haugen10 and Tuhina Neogi11, and OARSI Early-stage Symptomatic Knee Osteoarthritis Initiative, 1University of Toronto, Toronto, ON, Canada, 2Boston University, Boston, MA, 3Shanghai Sixth People's Hospital, Shanghai, China (People's Republic), 4University of West Florida, Pensacola, FL, 5Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 6Women's College Hospital, Toronto, ON, Canada, 7The University of Western Ontario, London, ON, Canada, 8,Lund University, Lund, Sweden, 9Lund University, Lund, Sweden, 10Diakonhjemmet Hospital, Oslo, Norway, 11Boston University Chobanian & Avedisian School of Medicine, Boston, MA

    Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). In individuals with undiagnosed knee…
  • Abstract Number: 1640 • ACR Convergence 2024

    ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis

    Eugenio De Miguel1, Iñigo Hernández-Rodríguez2, Maite Silva-Diaz3, Joaquin María Belzunegui:4, Patricia Moya5, Marina Tortosa-Cabañas6, Vanessa Andrea Navarro7, Joan Calvet8, Ivette Casafont-Solé9, Jose A Román-Ivorra10, Selene Labrada-Arrabal11, Margarida Vasques Rocha:12, Carlota L Iñiguez:13, Vanesa Hernández-Hernández14, Cristina Campos-Fernández15, María Alcalde Villar:16, Antonio Juan-Mas17, Francisco-Javier Prado-Galbarro18, Itziar Calvo19, Julio Sánchez-Martín20, Javier Narvaez-García21 and Ricardo Blanco-Alonso22, and ARTESER Project Collaborative Group, 1Hospital Universitario La Paz, Madrid, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 3Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 4H de Donostia, Donostia-San Sebasti, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Hospital Universitario Ramón y Cajal, Madrid, Spain, 7Hospital Moisès Broggi, Sant Joan Despí, Spain, 8Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, 9Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, 10Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain, 11Hospital del Mar, Barcelona, Spain, 12Hospital Universitario Araba, Vitoria, Spain, 13Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, 14Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, 15Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, 16Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 17Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, 18Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Unidad Xochimilco,, Mexico, Mexico, 19Hospital Universitario de Basurto, Bilbao, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Hospital Universitario de Bellvitge, Barcelona, Spain, 22Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: The diagnosis of giant cell arteritis (GCA) has been guided for years by the ACR 1990 classification criteria but the emergence of the image…
  • Abstract Number: 2111 • ACR Convergence 2024

    An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis

    Lauren King1, Armaghan Mahmoudian2, Jean Liew3, Quike Wang4, Ian Stanaitis5, Dieuwke Schiphof6, Leigh Callahan7, David Hunter8, Tom Appleton9, Aleksandra Turkiewicz10, Martin Englund11, Stefan Lohmander11, Ida Kristin Haugen12, Tuhina Neogi13, Gillian Hawker1 and Jos Runhaar6, and OARSI Early-stage Symptomatic Knee Osteoarthritis Initiative, 1University of Toronto, Toronto, ON, Canada, 2University of West Florida, Pensacola, FL, 3Boston University, Boston, MA, 4Shanghai Sixth People's Hospital, Shanghai, China (People's Republic), 5Women's College Hospital, Toronto, ON, Canada, 6Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 7University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, 8Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 9The University of Western Ontario, London, ON, Canada, 10,Lund University, Lund, Sweden, 11Lund University, Lund, Sweden, 12Diakonhjemmet Hospital, Oslo, Norway, 13Boston University Chobanian & Avedisian School of Medicine, Boston, MA

    Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). The goal is to establish…
  • Abstract Number: 2196 • ACR Convergence 2024

    Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings

    Suzanne Li1, Natalia Vasquez-Canizares2, Clare Pain3, Marinka Twilt4, Amra Adrovic5, Abdulrahman Alrasheed6, Simone Appenzeller7, ADELE CIVINO8, narendra bagri9, Patricia Costa Reis10, Muserref Cucueoglu11, Fatma Dedeoglu12, samundeeswari Deepak13, Jianghong Deng14, Dalia El-Ghoneimy15, Ivan Foeldvari16, Fernando Garcia-Rodriguez17, Marija Jelusic18, Ankur Jindal19, Ozgur Kasapcopur20, Maria Katsicas21, Archana Khan22, Raju Khubchandani23, Meiping Lu24, Hanna Lythgoe25, edoardo marrani26, Giorgia Martini27, Takako Miyamae28, Tomo Nozawa29, Seza Ozen30, Lidia Rutkowska-Sak31, Sunil Sampath13, Dieneke Schonenberg-Meinema32, Hongmei Song33, Betul Sozeri34, Hayakazu Sumida35, Maria Teresa Terreri36, Kathryn Torok37, Seyma Turkmen38, Dilara Unal38, Gong Yinv39, Emily Willis25, Rongjun Zheng24 and Brian Feldman40, and Pediatric International Consortium for Scleroderma, 1Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 2Children's Hospital at Montefiore, Bronx, NY, 3Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, 4Alberta Children's Hospital, Calgary, AB, Canada, 5Koc University Hospital, Istanbul, Turkey, 6King Abdullah Specialized Children Hospital, Riyadh, Saudi Arabia, 7Unicamp, Campinas, SP, Brazil, 8Pediatric Rheumatology "Vito Fazzi" Hospital LECCE, LECCE, Italy, 9All India Institute of Medical Sciences, New Delhi, Delhi, India, 10Hospital de Santa Maria, Lisbon, Portugal, 11Hacettepe University, Ankara, Turkey, 12Boston Children's Hospital, Boston, MA, 13THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST, Newcastle upon Tyne, United Kingdom, 14Beijing Children's Hospital, Beijing, China, 15Children's Hospital, Ain Shams University, Cairo, Egypt, 16Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 17Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico, 18University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 19Postgraduate Institute of Medical Education and Research, Chandigarh, India, 20Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 21Hospital Garrahan, Buenos Aires, Argentina, 22SRCC Children's Hospital, Mumbai, India, Mumbai, India, 23The SRCC Children's Hospital, Mumbai, India, 24Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China (People's Republic), 25Royal Manchester Children's Hospital, Manchester, United Kingdom, 26Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, 27University of Udine University Hospital Santa Maria della Misericordia, Udine, Italy, 28Tokyo Women's Medical University, Tokyo, Japan, 29Yokohama City University, Yokohama, Japan, 30Department of Pediatrics, Hacettepe University, Ankara, Turkey, 31National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland, 32Amsterdam University Medical Center, Amsterdam, Netherlands, 33Peking Union Medical College Hospital, Beijing, China, 34University of Health Sciences, Istanbul, Turkey, 35The University of Tokyo, Tokyo, Japan, 36UNIFESP, São Paulo, SP, Brazil, 37Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 38University of Health Sciences, Umraniye Training and Research Hospital, Ankara, Turkey, 39Children's Hospital Affiliated to Fudan University, Shanghai, China (People's Republic), 40Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Despite the high morbidity and mortality risk associated with juvenile systemic sclerosis (jSSc), evidence to guide management is limited.  No jSSc clinical trials have…
  • Abstract Number: 0543 • ACR Convergence 2023

    Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015

    Hilde Haukeland1, Sigrid Reppe Moe1, Cathrine Brunborg2, Antonela Botea3, Nenad Damjanic4, Gro Wivestad5, Heidi Øvreås6, Thea Bøe7, Torhild Garen1, Anniken Orre8, Helga Sanner9, Øyvind Molberg10 and Karoline Lerang9, 1Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 2Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 3Betanien Hospital, Department of Rheumatology, Skien, Norway, 4Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, 5Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, 6Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, 7Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, 8Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, 9Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, 10University of Oslo, Institute of Clinical Medicine, Oslo, Norway

    Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
  • Abstract Number: 0711 • ACR Convergence 2023

    IgA Vasculitis in a Diverse Adult Patient Population

    Michelle Toker1, Urmi Khanna1, Roya Nazarian1, Adhya Mehta2, Bibi Ayesha1, Anand Kumthekar1 and Benedict Wu1, 1Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 2Jacobi Medical Center, Bronx, NY

    Background/Purpose: Immunoglobulin-A (IgA) Vasculitis (IgAV) is a small-vessel vasculitis that is primarily diagnosed based on the European League Against Rheumatism (EULAR) criteria. There is limited…
  • Abstract Number: 1059 • ACR Convergence 2023

    Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data

    Anne Bass1, Fenglong Xie2, Alexa Meara3, Deanna Jannat-Khah4 and Jeffrey Curtis2, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2University of Alabama at Birmingham, Birmingham, AL, 3The Ohio State University Wexner Medical Center, Columbus, OH, 4Hospital For Special Surgery, New York, NY

    Background/Purpose: Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) has been suggested to occur in approximately 3-6% of ICI-treated patients with cancer1 but most studies…
  • Abstract Number: 1131 • ACR Convergence 2023

    Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort

    Choon Guan Chua1, Weida Chew1, Jeggrey Kay Wee Kam1, Hwee-Pin Phua1, Chengzi Chow1, Carol Yee-Leng Ng1, Wei-Yen Lim1, Ru Sin Lim1, Jereme Yijin Gan1, Mung-Ee Loh1, Tianrong Yeo2, David Zhiwei Law1, Stephrene Seok Wei Chan3, Amanda Francesca Ya-Fang Cheang4, Yong-Howe Ho1 and Charles Kien-Fong Vu1, 1Tan Tock Seng Hospital, Singapore, Singapore, 2National Neurology Institute, Singapore, Singapore, 3National University Hospital, Singapore, Singapore, 4Woodlands Health Campus, Singapore, Singapore

    Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that is heterogenous and can result in organ failure. To understand the disease profile of our local…
  • Abstract Number: 1136 • ACR Convergence 2023

    Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations

    Paula García Escudero1, Marta López i Gómez2, Marta López Maraver3, PALOMA VELA4, María Rodríguez Laguna5, carolina Merino6, Ana Victoria Orenes Vera7, Clara García Belando8, Diego Dios Santos9, Jose Alberto Miranda Filloy10, Francisco Javier Toyos Sáenz de Miera11, Alicia Garcia Dorta12, Ignacio Vázquez13, José Ángel Hernández Beriain14, MARIA ELVIRA DIEZ ALVAREZ15, Marta Ibáñez Martínez16, Beatriz Frade Sosa17, Judit Font Urgelles18, Meritxell Salles Lizarzaburu19, Elena Riera Alonso20, Ernesto Trallero Araguás21, Berta Magallanes López22, Joaquín Belzunegui Otano23, Carlos de Miguel Sánchez24, Zuriñe Ortiz de Zárate Caballero25 and Jaime Calvo Alén26, 1Hospital Universitario Araba, Bilbao, Spain, 2Hospital Universitario de Araba, Pamplona, Spain, 3Hospital Universitario de Araba, Vitoria, Spain, 4Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 5H. Clínico San Carlos, Madrid, Spain, 6Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, 7H. Arnau de Vilanova, Valencia, Spain, 8Hospital Los Arcos del Mar Menor, Murcia, Spain, 9Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 10C. H. U. Lucus Augusti, Lugo, Spain, 11Hospital Virgen Macarena, Sevilla, Spain, 12Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 13H. U. Dr. Peset, Valencia, Spain, 14Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 15Rheumatology, Hospital Universitario de León, León, Spain, 16C. A. U. de Salamanca, Salamanca, Spain, 17Hospital Clínic de Barcelona, Barcelona, Spain, 18Hospital Universitario Germans Trías i Pujol, Barcelona, Spain, 19C. H. de Manresa - Fundació Althaia, Barcelona, Spain, 20Hospital Universitario Mútua Terrassa, Barcelona, Spain, 21Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, 22Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 23Hospital Universitario Donosti, Donosti, Spain, 24Hospital Universitario de Araba, Hematology, VItoria, Spain, 25Hospital Universitario de Araba, Internal Medicine, Vitoria, Spain, 26Hospital Universitario Araba, Vitoria, Spain

    Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…
  • Abstract Number: 1175 • ACR Convergence 2023

    Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis

    Yusra Hasan1, Katharine Ching Chung2, Dana Ascherman3, Siamak Moghadam-Kia4, Chester V. Oddis3 and Rohit Aggarwal3, 1CHI Health Creighton University Medical Center, Omaha, NE, 2University of Pittsburgh Medical Center, Mckeesport, PA, 3University of Pittsburgh, Pittsburgh, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…
  • Abstract Number: 1228 • ACR Convergence 2023

    Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach

    Caterina Matucci-Cerinic1, helene Palluy2, Sulaiman Al-Mayouf3, Paul Brogan4, Luca Cantarini5, Ahmet Gul6, Ozgur Kasapcopur7, Jasmin B. Kuemmerle-Deschner8, Seza Ozen9, david saadoun10, Farhad Shahram11, Francesca Bovis12, Eugenia mosci13, Nicolino Ruperto14, Marco Gattorno15 and Isabelle Kone-Paut16, 1DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, 2Pediatric rheumatology and CEREMAIA, Bicêtre hospital, APHP, University of Paris Saclay, Paris, France, 3King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, 4UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 5Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, 6Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, 8med.uni-tuebingen, Tübingen, Germany, 9Hacettepe University Medical Faculty, Ankara, Turkey, 10Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire, F-75013, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière., Neuilly sur Seine, France, 11Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, 12Dept of Health Sciences (DISSAL), University of Genoa, Genova, Italy, 13UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, IRCCS Istituto Giannina Gaslini, Genova, Italy, 14IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 15UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 16Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France

    Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology